Effect of Walnuts on Cognitive Function and Gut Microbiome in Older Adults
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Contact
Study Contact
- Name: Emily Ho, PhD
- Phone Number: 541-737-9559
- Email: emily.ho@oregonstate.edu
Study Contact Backup
- Name: Sandra Uesugi, RN, BSN, MS
- Phone Number: 541-737-3594
- Email: sandra.uesugi@oregonstate.edu
Study Locations
-
-
Oregon
-
Corvallis, Oregon, United States, 97331
- Oregon State University
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Age 55 years or older
- Able to hear well enough to understand spoken instructions and questions
- Able to see well enough to read and respond to printed instructions and fill out questionnaires (corrective lenses are allowed)
- Able to write legibly and move a computer joystick with at least one hand (i.e., no injury or connective tissue or joint disorder that would impair ability to write or make hand movements)
- Able to speak, read, and understand English
- Score of greater than 79 on water maze learning task
- Willing to maintain current eating patterns
- Willing and able to complete the cognitive tests
- Willing to stop consuming almonds, Brazil nuts, cashews, chestnuts, hazelnuts, macadamia nuts, peanuts, pecans, pistachios, walnuts, persimmons and pomegranates for 14 weeks. - are nuts or contain ellagitannins or ellagic acid - compounds/foods of interest for this study
- Willing to limit oak aged wines and spirits to 1 serving/day and limit blackberries (including similar berries like boysenberries, marionberries, and olallieberries), cloudberries, cranberries, currants, elderberries, lingonberries, raspberries, strawberries, wolfberries, other native berries; guava, mango, muscadine grapes, nectarines, peaches, plums, pluots to 1 cup/day for 14 weeks; REMAIN CONSISTENT (consistent intake levels of): Coffee, tea, apple, apricots, blueberries, cherries, grapes (table/common)
- Willing to stop probiotic supplements 2 weeks prior to and during the study (14 weeks)
Exclusion Criteria:
- Consumption of walnuts, pecans, and chestnuts combined greater than 2 oz / week in the past 3 months.
- Use of oral antibiotics in the past month
- Regular use of oral anti-inflammatory medications in the past month
- Nut, wheat, or gluten allergy/intolerance
- Pregnant or planning to become pregnant during the study period
- Weighs less than 110 pounds
- Diagnosis of sickle cell disease
- Susceptibility to motion sickness
- Consumes 3 or more alcoholic drinks daily
- History of smoking tobacco products, including e-cigarettes and vaporizers in the past 2 years (smokeless tobacco use not exclusionary)
- Use of psilocybin or cannabis products (including CBD-only products) in the past 2 years
- Current treatment for alcohol or other substance use disorder
- History of heart attack, heart failure, or stroke, including transient ischemic attack
- History of liver disease or kidney disease requiring dialysis
- History of cancer in the past 5 years (Skin cancer that was only surgically treated is not exclusionary)
- History of bariatric surgery (e.g., gastric bypass, gastric banding, sleeve gastrectomy, etc.) or disorders (e.g., Crohn's disease, unmanaged celiac disease, ulcerative colitis)
- History of thyroid disorder that requires medication, but subject is not taking medication
- History of chronic bronchitis or emphysema
- Diagnosis of dementia or Alzheimer's disease
- History of head injury requiring hospitalization or loss of consciousness > 5 minutes
- History of chronic migraines (for at least 3 months, headache occurring on 15 or more days per month, where at least 8 of those headache days have migraine symptoms)
- Blood pressure above 159 (systolic) or 99 (diastolic) mm Hg
- Corrected vision worse than 20/50
- Score of less than 10/15 on Ishihara color vision test or diagnosis of color blindness
- Score of less than 26/30 on Mini-Mental State Exam
- Score of greater than 15 on Center for Epidemiologic Depression survey
- History of disease or disorder which causes cognitive impairment, including but limited to: attention-deficit/hyperactivity disorder (ADHD), amyotrophic lateral sclerosis, autism, bipolar disorder, Down's syndrome, encephalitis, epilepsy/seizures, human immunodeficiency virus (HIV), Huntington's disease, Korsakoff's psychosis, multiple sclerosis, Parkinson's disease, or psychotic disorders (e.g., schizophrenia, schizoaffective disorder, schizophreniform disorder)
- Current and regular use of any of the following medications: insulin, opioids, anti-seizure medications, psychotropic medications: stimulants, anti-psychotics, or medications that cause daytime drowsiness or difficulty concentrating
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Basic Science
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Active Comparator: Walnuts
Daily consumption of 1.5 ounces (42.5 g) of plain walnuts for 12 weeks
|
Daily consumption of 1.5 ounces of plain walnuts for 12 weeks
|
|
Placebo Comparator: Crackers
Daily consumption of non-whole grain crackers for 12 weeks (caloric equivalent to 1.5 ounces of plain walnuts)
|
Daily consumption of non-whole grain crackers for 12 weeks (caloric equivalent to 1.5 ounces of plain walnuts)
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Cognitive function - speed of processing
Time Frame: 0 and 12 weeks
|
Change from baseline at week 12: age adjusted standard scores (higher score reflects positive outcome)
|
0 and 12 weeks
|
|
Gut microbiome composition
Time Frame: 0 and 12 weeks
|
Change from baseline at week 12: microbiome composition
|
0 and 12 weeks
|
|
Lipid oxidation levels
Time Frame: 0 and 12 weeks
|
Change from baseline at week 12: plasma malondialdehyde (MDA)
|
0 and 12 weeks
|
|
Gut permeability and health: Inflammatory biomarkers
Time Frame: 0 and 12 weeks
|
Change from baseline at week 12: Gut inflammatory biomarkers fecal calprotectin and myeloperoxidase
|
0 and 12 weeks
|
|
Biomarkers of inflammation
Time Frame: 0 and 12 weeks
|
Change from baseline at week 12: Plasma inflammatory markers (ex.
CRP and IL-6)
|
0 and 12 weeks
|
|
Cognitive function - memory, age adjusted
Time Frame: 0 and 12 weeks
|
Change from baseline at week 12: age adjusted standard scores (higher score reflects positive outcome)
|
0 and 12 weeks
|
|
Cognitive function - memory, proximity
Time Frame: 0 and 12 weeks
|
Change from baseline at week 12: proximity (lower score reflects positive outcome)
|
0 and 12 weeks
|
|
Cognitive function - cognitive flexibility, age adjusted
Time Frame: 0 and 12 weeks
|
Change from baseline at week 12: age adjusted standard scores (higher score reflects positive outcome)
|
0 and 12 weeks
|
|
Cognitive function - cognitive flexibility, proximity
Time Frame: 0 and 12 weeks
|
Change from baseline at week 12: proximity (lower score reflects positive outcome)
|
0 and 12 weeks
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Urolithin concentrations
Time Frame: 0 and 12 weeks
|
Change from baseline at week 12: urolithin A and urolithin B concentrations in urine
|
0 and 12 weeks
|
|
Blood pressure
Time Frame: 0 and 12 weeks
|
Change from baseline at week 12: systolic and diastolic blood pressure
|
0 and 12 weeks
|
|
Weight
Time Frame: 0 and 12 weeks
|
Change from baseline at week 12: weight
|
0 and 12 weeks
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Investigators
Investigators
- Principal Investigator: Emily Ho, PhD, Oregon State University
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- LPI-1153
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.